en · de · es · fr · pt
semax-notes.peptides1126.com › Info › Semax Peptide Background And Identity — Field Notes

Semax Peptide Background And Identity — Field Notes

By Editorial Desk · published 2026-03-24 · last reviewed 2026-04-14 · Info

Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.

Semax Peptide Background and Identity

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Analytical Testing And Storage

Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.

Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.

The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptide (ACTH fragment analog)Not a steroid; does not belong to the melanocortin agonist drugs by marketing category
Molecular formulaC37H51N9O10S (commonly cited)Reported values vary slightly with salt and counter-ion content
AppearanceWhite to off-white lyophilized powderA single batch may appear as a loose cake or fluffy solid
SolubilityFreely soluble in water and aqueous bufferStock solutions are usually prepared in sterile water or saline
Typical storage−20 °C or below, desiccated and protected from lightSeal opened vials promptly to limit moisture uptake

Semax Structure and Research Background

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.

Related pages on this site

Handling, Storage, and Research Status

Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.

Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

化学性质与分析表征

从分子层面看,Semax 是线性七肽,没有二硫键、糖基或脂链修饰,N 端为游离氨基,C 端为游离羧基。分子含组氨酸与谷氨酸侧链,因此在水和甲醇等极性溶剂中溶解良好,在非极性溶剂中溶解有限。计算分子量约为 814 Da,与其质子化离子的质荷比吻合,可用于质谱确认。

稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定,遇到强碱或长时间高温则明显断裂;甲硫氨酸侧链容易被氧化成亚砜,使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间,配制后的水溶液通常需要冷藏并尽快用完。

Reference notes

(2026) reconstruct the evolutionary history of members of the genus Arvicola in Western Europe during the late Middle and Late Pleistocene on the basis of the study of morphology of teeth from the Lazaret Cave and Moula-Guercy sites (France), Abauntz Cave, Cova Eirós (Spain) and Trou Al'Wesse (Belgium), interpreted as consistent with a complex biogeographic history including multiple dispersals into Western Europe and subsequent local extinctions and recolonizations. New fossil material of members of the genus Byzantinia, providing new information on the morphology of teeth of members of this genus and their evolution, is described from the Miocene strata of the Zahleh Formation (Lebanon) by López-Antoñanzas et al. (2026). A study on the phylogenetic relationships and evolutionary history of extant and extinct hamsters is published by Dirnberger et al. (2026). Bujalska et al. (2026) reconstruct the evolutionary history of European small hamsters on the basis of mitochondrial genomes from Late Pleistocene and Holocene remains from Central and Western Europe, the Balkans and Anatolia, identifying evidence of presence of the winter white dwarf hamster in Central Europe during the Late Pleistocene. Pacheco-Castro, Carranza-Castañeda & Wang (2026) report the discovery of fossil material of Sigmodon minor from the Pliocene strata of the San Miguel de Allende Basin, representing the first record of the species from central Mexico and its southernmost known record in North America.

== Mechanism of toxicity == Once azinphos-methyl is absorbed it can cause neurotoxic effects, like other organophosphate insecticides. At high concentrations AzM itself can be toxic because it can function as an acetylcholinesterase (AChE) inhibitor. But its toxicity is mainly due to the bioactivation by a cytochrome P450 (CYP450)-mediated desulfuration to its phosphate triester or oxon(gutoxon) (see figure 2). Gutoxon can react with a serine hydroxyl group at the active site of the AChE. The active site is then blocked and AChE is inactivated. Under normal circumstances acetylcholinesterase rapidly and efficiently degrades the neurotransmitter acetylcholine (ACh) and thereby terminates the biological activity of acetylcholine. Inhibition of AChE results in an immediate accumulation of free unbound ACh at the ending of all cholinergic nerves, which leads to overstimulation of the nervous system.

Glycinamide is an organic compound with the molecular formula H2NCH2C(O)NH2. It is the amide derivative of the amino acid glycine. It is a water-soluble, white solid. Amino acid amides, such as glycinamide are prepared by treating the amino acid ester with ammonia. It is a ligand for transition metals, related to amino acid complexes. As a neutral ligand, it binds through the amine. In some complexes, it binds through the amine and the carbonyl oxygen, forming a five-membered chelate ring. The hydrochloride salt of glycinamide, glycinamide hydrochloride, is one of Good's buffers with a pH in the physiological range. Glycinamide hydrochloride has a pKa near the physiological pH (8.20 at 20°C), making it useful in cell culture work. Its ΔpKa/°C is -0.029 and it has a solubility in water at 0 °C of 6.4 M. Glycinamide is a reagent used in the synthesis of glycineamide ribonucleotide (an intermediate in de novo purine biosynthesis).

The Bergmann azlactone peptide synthesis is a classic organic synthesis process for the preparation of dipeptides. In the presence of a base, peptides are formed by aminolysis of N-carboxyanhydrides of amino acids with amino acid esters (1). This reaction can be looked at in further detail by Bailey. The resulting peptide is then protected by esters of benzylchroroformate in order to keep the amino groups intact (2). This mechanism serves as a source of protection for the amino group in the amino acid. The ester will block the amino group from binding with other molecules. The last step in this reaction is the cyclization of the N-haloacylamino acids with an acetanhydride. This will result in the expected azlactone (3). The reaction with a second amino acid allows for the ring to open, later forming an acylated unsaturated dipeptide. The reaction happens in a step-wise function which allows for the amino group to be protected and the azlactone to be produced. Catalytic hydrogenation and hydrolysis then take place in order to produce the dipeptide (4).

The positive transcription elongation factor, P-TEFb, is a multiprotein complex that plays an essential role in the regulation of transcription by RNA polymerase II (Pol II) in eukaryotes. Immediately following initiation Pol II becomes trapped in promoter proximal paused positions on the majority of human genes (Figure 1). P-TEFb is a cyclin dependent kinase that can phosphorylate the DRB sensitivity inducing factor (DSIF) and negative elongation factor (NELF), as well as the carboxyl terminal domain of the large subunit of Pol II and this causes the transition into productive elongation leading to the synthesis of mRNAs. P-TEFb is regulated in part by a reversible association with the 7SK snRNP. Treatment of cells with the P-TEFb inhibitors DRB or flavopidirol leads to loss of mRNA production and ultimately cell death. P-TEFb was identified and purified as a factor needed for the generation of long run-off transcripts using an in vitro transcription system derived from Drosophila cells.

Sources: en.wikipedia.org

Reference notes

==== Notable incidents ==== The state of Florida used midazolam to execute William Frederick Happ in October 2013. The state of Ohio used midazolam in the execution of Dennis McGuire in January 2014; he was heavily anesthetized and unconscious within 4 minutes of starting the administration of midazolam and 20 more minutes after that point before he was declared medically dead. Controversy arose after he was observed gasping and appeared to choke during that time according to reporters who were allowed to be present, leading to questions about the dosing and timing of the drug administration, as well as the choice of drugs. The usage of midazolam in executions became controversial after condemned inmate Clayton Lockett apparently regained consciousness and started speaking midway through his 2014 execution when the state of Oklahoma attempted to execute him with an untested three-drug lethal injection combination including 100 mg of midazolam. Prison officials reportedly discussed taking him to a hospital before he was pronounced dead of a heart attack 40 minutes after the execution began. An observing doctor stated that Lockett's vein had ruptured. It is not clear whether his death was caused by one or more of the drugs or by a problem in the administration procedure, nor is it clear what quantities of vecuronium bromide and potassium chloride were released to his system before the execution was cancelled.

=== Regulatory status === There are currently no approved drug products containing 5-HTP approved by the FDA. All available 5-HTP products are nutraceuticals and are as such not regulated or verified for purity, integrity, or clinical efficacy or safety, mandating caution regarding human consumption. As of 25 August 2020, Hungary added 5-HTP to the controlled psychoactive substances list, prohibiting production, sale, import, storage and use, becoming the first country to do so.

Evidence from the study of the pelvis and hindlimbs of Cyonasua, indicative of morphological similarities to bones of scansorial and terrestrial generalist carnivorans such as members of the genera Galictis, Meles and Arctictis, is presented by Tarquini et al. (2026). Tseng (2026) describes the first known partial skeleton of Leptarctus wortmani from the Hemphillian strata from the Rome Beds (Oregon, United States), providing evidence of morphology of the postcranial skeleton similar to those of extant badgers belonging to the genus Meles. Lopatin et al. (2026) describe a molar of a member of the genus Mellivora from the Pleistocene strata from the Tham Hai Cave, representing the first known record of Mellivorinae in Southeast Asia. A new specimen of Cernictis hesperus, providing new information on the anatomy of members of this species, is described from the (probably late Hemphillian) strata of the Pinole Tuff Formation (California, United States) by Tseng (2026). A well-preserved cranium of a Pleistocene sable is described from the Ogorokha Site (Sakha Republic, Russia) by Boeskorov et al. (2026). Sotnikova et al. (2026) report the discovery of new fossil material of large-bodied wolverines from the Pleistocene strata from the Indigirka River basin and New Siberia (Sakha Republic, Russia), and interpret their large size as likely to be physiological adaptation to the mammoth steppe environment. Rule et al.

== Dystrophies, myositis, and motor neuron conditions == Pathologic atrophy of muscles can occur with diseases of the motor nerves or diseases of the muscle tissue itself. Examples of atrophying nerve diseases include Charcot-Marie-Tooth disease, poliomyelitis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and Guillain–Barré syndrome. Examples of atrophying muscle diseases include muscular dystrophy, myotonia congenita, and myotonic dystrophy. Changes in Na+ channel isoform expression and spontaneous activity in muscle called fibrillation can also result in muscle atrophy. A flail limb is a medical term which refers to an extremity in which the primary nerve has been severed, resulting in complete lack of mobility and sensation. The muscles soon wither away from atrophy.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Where did Semax originate?

It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.

Is Semax a licensed medicine?

It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.

How is semax purity measured?

Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.

Network